Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 729-736 , May 2011

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

  • Paul Shaughnessy

      Affiliations

    • Texas Transplant Institute, San Antonio, Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Paul Shaughnessy, MD, Texas Transplant Institute, 7711 Louis Pasteur, Suite 704, San Antonio, TX 78229.
    • ,
  • Miguel Islas-Ohlmayer

      Affiliations

    • Texas Transplant Institute, San Antonio, Texas
    • ,
  • Julie Murphy

      Affiliations

    • Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado
    • ,
  • Maureen Hougham

      Affiliations

    • Texas Transplant Institute, San Antonio, Texas
    • ,
  • Jill MacPherson

      Affiliations

    • Texas Transplant Institute, San Antonio, Texas
    • ,
  • Kurt Winkler

      Affiliations

    • Texas Transplant Institute, San Antonio, Texas
    • ,
  • Matthew Silva

      Affiliations

    • Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts
    • ,
  • Michael Steinberg

      Affiliations

    • Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts
    • ,
  • Jeffrey Matous

      Affiliations

    • Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado
    • ,
  • Sheryl Selvey

      Affiliations

    • Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts
    • ,
  • Michael Maris

      Affiliations

    • Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado
    • ,
  • Peter A. McSweeney

      Affiliations

    • Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado

Received 21 July 2010 ,Accepted 23 August 2010.

References 

  1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545
  2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet. 2002;359:2065–2071
  3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91–97
  4. Vose JM, Ho AD, Coiffier B, et al. Advance in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009;50:1412–1421
  5. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969
  6. Seggewiss R, Buss EC, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S. Kinetics of peripheral blood stem cell mobilization following G-CSF supported chemotherapy. Stem Cells. 2003;21:568–574
  7. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059–2064
  8. Meldgaard Knudsed L, Jensen L, Gaarsdal E, Nikolaisen K, Johnson HE. A comparative study of sequential priming and mobilization of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant. 2000;26:717–722
  9. Dazzi C, Cariello A, Rosti G, et al. Is there any difference in PBPC mobilization between cyclophosphosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin’s lymphoma?. Leuk Lymphoma. 2000;3963-40:301–310
  10. Koc ON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol. 2000;9:1824–1830
  11. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or borezomib-containing regimens. Blood. 2009;114:1729–1735
  12. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–1318
  13. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo controlled trial of plerixafor plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–4773
  14. DiPersio JF, Standtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–5726
  15. Overview physician fee schedule. United States (US) Department of Health and Human Services Centers for Medicaid Services (HHS/CMS). Available at: http://www.cms.gov/PhysicianFeeSched/. Updated May 25th, 2010. Accessed July 2009-March 2010.
  16. Hosing C, Smith VR, Rhodes BA, et al. An analysis of the costs associated with peripheral blood hematopoietic progenitor cell mobilization, collection and cryopreservation in patients with lymphomas undergoing autologous stem cell transplantation. Blood. 2008;112;Abstract 2377
  17. Wolf MS, Fitzner KA, Powell EF, et al. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among veterans. J Clin Oncol. 2005;23:8877–8883
  18. Kuderer NM, Dale DC, Crawford J, Cosler L, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266
  19. Pusic I, Fiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–1056

 Financial disclosure: See Acknowledgments on page 736.

PII: S1083-8791(10)00367-8

doi: 10.1016/j.bbmt.2010.08.018

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 729-736 , May 2011

Article Tools

* Image Usage & Resolution